Table 1.

Reported trials of ICI single agent therapy in advanced cervical cancer.

Trial	No. of Subjects	Included Subjects	Intervention	ORR (%)	mDOR (Months)	Survival (Months)
EMPOWER-CERVICAL 1/GOG-3016/ENGOT-CX9 [15]	608	PDL1 unselected ≥1 prior line of therapy	Cemiplimab 350 mg 3 weekly vs. Investigator choice chemotherapy	16.4 vs. 6.3	16.4 vs. 6.9	mPFS: 2.8 vs. 2.9 (HR = 0.75 [0.63–0.89]) mOS: 12.0 vs. 8.5 (HR = 0.69 [0.56–0.84])
KEYNOTE-028 [16]	24	PD-L1 ≥ 1% (modified proportion score) PD on prior therapy	Pembrolizumab 10 mg/kg, 2 weekly	17	5.4 m	mPFS 2 mOS 11
KEYNOTE-158 [17]	98	PDL1 unselected PD on prior therapy	Pembrolizumab 200 mg 3 weekly	12.2 (PDL1 unselected) 14.6 (PDL1 CPS ≥ 1)	NR	mPFS 2.1 mOS 9.4 (ITT)
CHECKMATE-358 [18] cervical cohort	19	≤2 prior lines of therapy Excluded HPV negative	Nivolumab 240 mg 2 weekly	26.3	NR	mPFS 5.1 mOS 21.9
NRG-GY002 [19]	25	PDL1 unselected PD on prior therapy	Nivolumab 3 mg/kg 2 weekly	4	3.8	mPFS 3.5 mOS 14.5
Lheureux et al. [20]	42	PDL1 unselected	Ipilimumab 10 mg/kg 3 weekly (4 cycles) → 12 weekly maintenance (to 1 year)	3	-	mPFS 2.5 mOS8.5

mDOR, median duration of response; ORR, objective response rate; HR, hazard ratio; mOS, median overall survival; mPFS, median progression free survival; PD, progressive disease; m, months; NR, not reached.